Jun Hyung Lee
Research Subjects
Jun Hyung Lee has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Dong-Hoon Jin
Department of Convergence Medicine, Asan Institute for Life Science, Asan Medical Center, Seoul, South Korea
37 shared publications - Mingee Choi
Wellmarkerbio Co., Ltd., Seoul, Republic of Korea
37 shared publications - Bomi Kim
Department of Pathology, College of Medicine, Inje University, Haeundae Paik Hospital, Busan, Republic of Korea
36 shared publications - Dong Kwan Kim
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
36 shared publications - Dong-In Koh
Wellmarkerbio Co., Ltd., Seoul, Republic of Korea
36 shared publications - Hong-Rae Jeong
Wellmarkerbio Co., Ltd., Seoul, Republic of Korea
36 shared publications
Latest Publications
- 12 August 2026
- Published by Springer Nature in Nature Chemical Biology
- p. 1-2
A dual assault on KRAS
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
The combination efficacy of anti-PD-1 and WM-A1 in cancer-PBCM co-culture assay.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
The combination efficacy of anti-PD-1 and WM-A1 in cancer-PBCM co-culture assay.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
IGSF1 targeting antibody is developed and characterized by various methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
IGSF1 targeting antibody is developed and characterized by various methods
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Target identification was conducted to identify the counter-partner of IGSF1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Target identification was conducted to identify the counter-partner of IGSF1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Analysis of IGSF1 expression and the physiological characteristics.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Analysis of IGSF1 expression and the physiological characteristics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Antibodies used in the experiments.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Antibodies used in the experiments.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Primers and RNAs used in the experiments.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Primers and RNAs used in the experiments.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Regulating of expression of Igsf1 is not critical for the proliferation, migration and invasion of cancer cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Regulating of expression of Igsf1 is not critical for the proliferation, migration and invasion of cancer cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
WM-A1 induces T cell activation in vitro and in vivo.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
WM-A1 induces T cell activation in vitro and in vivo.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Cytokine profile released from PBMCs co-cultured with NCI-H292-IGSF1 O/E cancer cell line.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
Cytokine profile released from PBMCs co-cultured with NCI-H292-IGSF1 O/E cancer cell line.